Why did FDA remove old ranitidine in 2020?

FDA asked makers to remove the older ranitidine drugs in April 2020. It later approved a new formula. Check the date and product for each action.

What did FDA request on April 1, 2020?

It asked makers to withdraw the then-marketed ranitidine drugs. NDMA is a chemical impurity. FDA found it could rise with time or heat.

The action included prescription and over-the-counter products. It was a product-safety decision, not a finding that every former user had cancer or that one person’s illness was drug-caused.

Why did storage conditions matter?

The impurity could rise as the old product aged. Heat could also increase it. The level in a new sample was not the whole concern.

Selected product results varied. A laboratory table does not tell you how a particular bottle was stored or what a person actually took. Do not use a single sample as an individual exposure record.

Was this based only on one heated test?

No. FDA said heat in a test could create more impurity. It used a lower-heat method and later acted on findings about product storage.

The agency’s method criticism does not erase every impurity concern. Its simulated stomach-fluid result also belongs to a laboratory model, not a clinical test proving all users were safe.

Was ranitidine still subject to the same action after 2025?

FDA approved new tablets in November 2025 after changes and tests. They use a new formula. The old notice does not describe every later product.

The approval addresses impurity formation and includes updated storage directions. It does not cancel the historical record or decide a past legal claim. Discuss the actual medicine with your clinician.

Does Zantac 360 use the same active ingredient?

The Zantac 360 label names famotidine. That is a different drug from ranitidine. Check the ingredient rather than the brand word alone.

A label can help identify a medicine; it does not prove what you purchased years ago. This page gives no dose or stop-and-switch instruction based on an older news notice.

Did the withdrawal prove a cancer claim?

No. A safety action does not prove personal cause. A 2023 study found no clear overall cancer rise against other acid drugs. It has limits.

The study did not measure every person’s actual use or impurity exposure. Read the product record and clinical evidence as different forms of evidence. Your doctor and lawyer address different personal questions.